1. Scrip

Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says

 
• By Jessica Merrill

Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.

Hand Holding translucent credit card
Sanofi tries to be more transparent on drug pricing • Source: Shutterstock

Sanofi took a strike against attacks on the high prices of insulin products in its 2019 drug pricing report, claiming that the debate around insulin prices doesn't match the company's drug pricing history.

"Despite the rhetoric about skyrocketing insulin prices, the net price of insulin has been falling for five consecutive years, making...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.